Head-to-Head: which COVID booster works better?

NCT ID NCT06065176

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested how well two different 2023-2024 updated COVID-19 vaccines (Novavax and Pfizer mRNA) protect adults from getting sick with COVID-19. About 1,200 adults who had already received at least two mRNA vaccine doses were randomly assigned to get either the Novavax or Pfizer booster, or no booster. Participants reported symptoms and took weekly COVID-19 tests for 20 weeks. The goal was to see which vaccine prevents symptomatic infections better and whether getting an updated booster is better than not getting one.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Novavax COVID-19 vaccine (2023-2024 formula) and Pfizer mRNA COVID-19 vaccine (2023-2024 formula)

What this could lead to

If this trial succeeds, it could show which updated COVID-19 vaccine offers better protection against symptomatic illness, helping guide future booster recommendations.

What could go wrong

This is a completed Phase 4 trial with 1,188 participants, so results are available but may not apply to everyone. Differences between vaccines might be small or not statistically significant.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Respiration Disorders respiratory tract infectious disorder upper respiratory tract disorder Vaccine-Preventable Diseases COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Utah School of Medicine

    Salt Lake City, Utah, 84108, United States